<DOC>
	<DOCNO>NCT00461630</DOCNO>
	<brief_summary>The primary aim ass effect raise HDL cholesterol ( good type ) extend release niacin/laropiprant 2g ( previously know MK−0524A ) versus match placebo risk heart attack coronary death , stroke , need arterial bypass procedure ( revascularisation ) people history circulatory problem . The secondary aim ass effect extend release niacin/laropiprant 2g daily heart attack , coronary death , stroke , revascularisation separately assess effect mortality overall various category cause death , effect major cardiovascular event people history different disease begin study .</brief_summary>
	<brief_title>Treatment HDL Reduce Incidence Vascular Events HPS2-THRIVE</brief_title>
	<detailed_description>Cardiovascular disease one leading cause morbidity mortality United Kingdom ( UK ) , well develop develop world . Finding new safe treatment reduce burden heart disease stroke therefore important contribution public health wider public interest . HPS2-THRIVE aim find whether combine niacin ( drug available 50 year ) new drug laropiprant ( reduce side-effects niacin ) beneficial . All participant HPS2-THRIVE establish cardiovascular disease therefore high risk recurrent vascular event ( myocardial infarction , stroke need arterial revascularisation ) . Two important risk factor recurrent event patient blood level LDL cholesterol positive association , HDL cholesterol level negative association . HDL cholesterol long know strong inverse correlation coronary heart disease ( CHD ) risk . But , randomize trial evidence beneficial effect raise HDL cholesterol limit . One effective HDL-raising agent niacin tolerability niacin severely limit flush cutaneous side-effects , appear mediate largely prostaglandin D. Laropiprant selective prostaglandin D receptor antagonist substantially reduce frequency intensity niacin-induced flushing . Daily oral dos extend release ( ER ) niacin plus Laropiprant 2g ( formerly MK-0524A ) well tolerate early study increase HDL cholesterol 20-25 % . The trial ass whether increase HDL cholesterol translate clinical benefit expect observational evidence . In addition , participant also provide effective LDL-lowering therapy , either simvastatin 40mg daily alone ezetimibe 10mg daily combination tablet . The complementary effect HDL ( good ) LDL ( bad ) cholesterol produce extended release niacin/laropiprant 2 g daily simvastatin 40 mg without ezetimibe 10 mg provide excellent treatment option patient vascular disease . However , trial far demonstrate clearly raise HDL cholesterol produce expect reduction cardiovascular risk . If HPS2-THRIVE able demonstrate reliably raise HDL cholesterol reduces risk cardiovascular event relevant hundred million people worldwide .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>History myocardial infarction ; Cerebrovascular atherosclerotic disease ( history presume ischaemic stroke , transient ischaemic attack carotid revascularisation ) Peripheral arterial disease ( i.e . intermittent claudication history revascularisation ) ; Diabetes mellitus evidence symptomatic coronary heart disease ( i.e . stable unstable angina , history coronary revascularisation acute coronary syndrome ) . Age &lt; 50 &gt; 80 year invitation Screening ; Less 3 month since presentation acute myocardial infarction , coronary syndrome stroke ( patient may enter later , appropriate ) ; Planned revascularisation procedure within 3 month randomization ( patient may enter later , appropriate ) ; Definite history chronic liver disease , abnormal liver function ( i.e . Alanine transaminase ( ALT ) &gt; 1.5 time upper limit normal ( ULN ) . ( Note : Patients history acute hepatitis eligible provide ALT limit exceed ) ; Breathlessness rest reason ; Severe renal insufficiency ( i.e . creatinine &gt; 200 µmol/L ) ; Evidence active inflammatory muscle disease ( e.g . dermatomyositis , polymyositis ) , Creatine kinase ( CK ) &gt; 3 time upper limit normal ( 3xULN ) ; Previous significant adverse reaction statin , ezetimibe , niacin laropiprant ; Active peptic ulcer disease ; Concurrent treatment : fibric acid derivative ( `` fibrate '' ) niacin ( nicotinic acid ) dose 100 mg daily ezetimibe combination either simvastatin 80 mg , atorvastatin 2080 mg , rosuvastatin 1040 mg daily potent cytochrome P450 3A4 ( CYP3A4 ) inhibitor , include : macrolide antibiotic ( erythromycin , clarithromycin , telithromycin ) ; systemic use imidazole triazole antifungal ( e.g . itraconazole , ketoconazole ) ; protease inhibitor ( antiretroviral drug HIV infection ) ; nefazodone ciclosporin amiodarone verapamil danazol ( Note : Patients temporarily take drug may rescreened discontinue , consider appropriate . ) ; Known poorly compliant clinic visit prescribe medication ; Medical history might limit individual 's ability take trial treatment duration study ( e.g . severe respiratory disease , history cancer evidence spread within last 5 year nonmelanoma skin cancer , recent history alcohol substance misuse )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>coronary heart disease</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>stroke</keyword>
	<keyword>peripheral arterial disease</keyword>
	<keyword>diabetes mellitus</keyword>
	<keyword>cholesterol</keyword>
	<keyword>HDL cholesterol</keyword>
	<keyword>simvastatin</keyword>
	<keyword>ezetimibe</keyword>
	<keyword>ER niacin</keyword>
	<keyword>laropiprant</keyword>
</DOC>